|
Ambrilia Biopharma Fiscal 2007 Results March 25th, 2008 9:00AM ET |
|||||
|
|||||
|
ABOUT AMBRILIA BIOPHARMA Ambrilia Biopharma Inc. (TSX:AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. In the latter part of 2007, Ambrilia adopted a new strategic plan, the primary objective of which is to progressively refocus R&D activities solely on antivirals. The strategy aims to capitalize on the Company’s broad portfolio and original expertise in virology. Today, Ambrilia’s product portfolio comprises of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery platform for cancer, an HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.), HIV integrase inhibitor and entry inhibitor programs, and an HCV polymerase inhibitor program. Ambrilia’s head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company’s web site:www.ambrilia.com |
|||||
|
|||||